BriaCell Therapeutics Corp. Warrant (BCTXW)

$

9
8
7
6
5
4
3
2
1
0
0
9
8
7
6
5
4
3
2
1
0
0
.
9
8
7
6
5
4
3
2
1
0
0
+$0.02 (+13.10%)Past DayToday's Volume:
9
8
7
6
5
4
3
2
1
0
0
9
8
7
6
5
4
3
2
1
0
0
9
8
7
6
5
4
3
2
1
0
0
,
9
8
7
6
5
4
3
2
1
0
0
9
8
7
6
5
4
3
2
1
0
0

Relative Strength Index (RSI)

- The Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. It is typically used to identify overbought or oversold conditions in financial markets.

- The RSI is calculated using the following formula:

RSI = 100 - (100 / (1 + RS))

Where RS is the ratio of the average gains to the average losses over a specified period.

- The default time period used is 14 days.

- RSI values range between 0 and 100.

RSI values above 70 are considered overbought (indicating a potentially opportune time to sell)

RSI values below 30 are considered oversold (indicating a potentially opportune time to buy)

RSI is not a perfect indicator and should be used in conjunction with other technical analysis tools, this is for informational purposes only and is not a substitute for professional financial advice.

About

Business overview of BriaCell Therapeutics Corp. Warrant (BCTXW)
BriaCell Therapeutics Corp is a clinical-stage immuno-oncology company. The group is developing an entirely new class of targeted immunotherapies to transform cancer care. Its product candidate Bria-IMT, is being evaluated in a pivotal Phase 3 combination study for metastatic breast cancer (MBC is breast cancer that has spread to other tissues). Bria-IMT is a targeted cell-based immunotherapy. The company is engaged in developing a Bria-OTS platform of personalized off-the-shelf cell-based immunotherapies. It is being evaluated in a Phase 1/2 clinical study and the treatment is initially focused on patients with breast cancer with an extension to prostate cancer, and other cancers.

Key Insights

Critical company metrics and information

  • Total Outstanding Shares

    36.18 Million Shares

  • Total Employees

    12

  • Dividend

    No dividend

  • IPO Date

    February 24, 2021

  • SIC Description

    Pharmaceutical Preparations

  • Primary Exchange

    NASDAQ

  • Type

    Warrant

  • Phone Number

    (604) 921-1810

  • Address

    3rd floor, bellevue centre, 235-15th str, West vancouver, A1, V7T 2X1

  • Homepage

    https://www.briacell.com

Historical Stock Splits

Execution DateSplit Amount
No Historical Stock Splits

Cash Flow Statement

November 1, 2023 to October 31, 2024
MetricValue
Net Cash Flow From Operating Activities, Continuing$-23.48 Million
Net Cash Flow From Operating Activities$-23.48 Million
Net Cash Flow$650,169.00
Net Cash Flow, Continuing$650,169.00

Income Statement

November 1, 2023 to October 31, 2024
MetricValue
Net Income/Loss Attributable To Noncontrolling Interest$-124,512.00
Diluted Average Shares$59.08 Million
Basic Earnings Per Share$-0.89
Net Income/Loss Attributable To Parent$-16.60 Million
Participating Securities, Distributed And Undistributed Earnings/Loss, Basic$140,082.00
Operating Expenses$29.98 Million

Balance Sheet

November 1, 2023 to October 31, 2024
MetricValue
Current Assets$8.22 Million
Current Liabilities$4.99 Million
Non-current Prepaid Expenses$1.21 Million
Liabilities$6.70 Million
Other Non-current Assets$421,975.00
Noncurrent Liabilities$1.71 Million

Historical Dividends

Announcement DatePayment DateRecord DateAmountFrequency
No historical dividends
Boost your savings and earn 4.35% APY with a Marcus by Goldman Sachs savings account, a rate that's 8x the national averagewhen signing up with Financhle. No fees, no minimum deposits, backed by the financial expertise of Goldman Sachs. Terms apply.
Earnings CalendarNews ArticlesAbout UsPrivacy & Cookies Info

ⓒ 2025 Financhle. All Rights Reserved.